Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 48c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $3.90, $0.48 better than the analyst estimate of $3.42. Revenue for the quarter came in at $751.8 million versus the consensus estimate of $735.62 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2021 EPS of $13.40-$14.70, versus the consensus of $14.45. Jazz Pharmaceuticals sees FY2021 revenue of $3.02-3.18 billion, versus the consensus of $3.11 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KB Home (KBH) Tops Q3 EPS by 16c
• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order